Brief: Veracyte Announces New Clinical Validation Data For Rna Sequencing-Based Afirma Medullary Thyroid Cancer Classifier Published In Thyroid
20/07/2022 22:09
July 20 (Reuters) - Veracyte Inc VCYT.O :
* VERACYTE ANNOUNCES NEW CLINICAL VALIDATION DATA FOR RNA
SEQUENCING-BASED AFIRMA MEDULLARY THYROID CANCER CLASSIFIER
PUBLISHED IN THYROID
* VERACYTE INC - GENOMIC TEST DEMONSTRATED 100 PERCENT
SENSITIVITY
AND 100 PERCENT SPECIFICITY FOR MTC
Source text for Eikon: ID:nBwbSwZ7Za
Further company coverage: VCYT.O
((reuters.briefs@thomsonreuters.com;))
Recent news on Veracyte
See all newsU.S. STOCKS ON THE MOVE-Vor Biopharma, Fair Isaac Corp, Plug Power
U.S. STOCKS ON THE MOVE-Snowflake, Cboe, Oracle
US STOCKS ON THE MOVE-Veracyte, Staar Surgical, Corning
Veracyte gains on data supporting use of prostate cancer test to guide treatment decisions
Corrected: U.S. RESEARCH ROUNDUP-Abbvie, Amazon, Illumina